دورية أكاديمية
Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study
العنوان: | Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study |
---|---|
المؤلفون: | Van Name, Michelle A., Kanapka, Lauren G., DiMeglio, Linda A., Miller, Kellee M., Albanese-O’Neill, Anastasia, Commissariat, Persis, Corathers, Sarah D., Harrington, Kara R., Hilliard, Marisa E., Anderson, Barbara J., Kelley, Jennifer C., Laffel, Lori M., MacLeish, Sarah A., Nathan, Brandon M., Tamborlane, William V., Wadwa, R. Paul, Willi, Steven M., Williams, Kristen M., Wintergerst, Kupper A., Woerner, Stephanie, Wong, Jenise C., DeSalvo, Daniel J. |
المساهمون: | Pediatrics, School of Medicine |
المصدر: | PMC |
بيانات النشر: | Sage |
سنة النشر: | 2023 |
المجموعة: | Indiana University - Purdue University Indianapolis: IUPUI Scholar Works |
مصطلحات موضوعية: | Behavioral intervention, Continuous glucose monitoring, Glycemic control, Hypoglycemia, Young children |
الوصف: | Objectives: Achieving optimal glycemic outcomes in young children with type 1 diabetes (T1D) is challenging. This study examined the durability of continuous glucose monitoring (CGM) coupled with a family behavioral intervention (FBI) to improve glycemia. Study design: This one-year study included an initial 26-week randomized controlled trial of CGM with FBI (CGM+FBI) and CGM alone (Standard-CGM) compared with blood glucose monitoring (BGM), followed by a 26-week extension phase wherein the BGM Group received the CGM+FBI (BGM-Crossover) and both original CGM groups continued this technology. Results: Time in range (70-180 mg/dL) did not improve with CGM use (CGM+FBI: baseline 37%, 52 weeks 41%; Standard-CGM: baseline 41%, 52 weeks 44%; BGM-Crossover: 26 weeks 38%, 52 weeks 40%). All three groups sustained decreases in hypoglycemia (<70 mg/dL) with CGM use (CGM+FBI: baseline 3.4%, 52 weeks 2.0%; Standard-CGM: baseline 4.1%, 52 weeks 2.1%; BGM-Crossover: 26 weeks 4.5%, 52 weeks 1.7%, P-values <.001). Hemoglobin A1c was unchanged with CGM use (CGM+FBI: baseline 8.3%, 52 weeks 8.2%; Standard-CGM: baseline 8.2%, 52 weeks 8.0%; BGM-Crossover: 26 weeks 8.1%, 52 weeks 8.3%). Sensor use remained high (52-week study visit: CGM+FBI 91%, Standard-CGM 92%, BGM-Crossover 88%). Conclusion: Over 12 months young children with T1D using newer CGM technology sustained reductions in hypoglycemia and, in contrast to prior studies, persistently wore CGM. However, pervasive hyperglycemia remained unmitigated. This indicates an urgent need for further advances in diabetes technology, behavioral support, and diabetes management educational approaches to optimize glycemia in young children. |
نوع الوثيقة: | article in journal/newspaper |
وصف الملف: | application/pdf |
اللغة: | English |
العلاقة: | Journal of Diabetes Science and Technology; Van Name MA, Kanapka LG, DiMeglio LA, et al. Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study. J Diabetes Sci Technol. 2023;17(4):976-987. doi:10.1177/19322968221084667; https://hdl.handle.net/1805/38470Test |
الإتاحة: | https://doi.org/10.1177/19322968221084667Test https://hdl.handle.net/1805/38470Test |
حقوق: | Publisher Policy |
رقم الانضمام: | edsbas.C04C7A2E |
قاعدة البيانات: | BASE |
الوصف غير متاح. |